Ultime notizie per Leap Therapeutics (NASDAQ:LPTX) Azioni

LEAP THERAPEUTICS INC

Leap Therapeutics

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

News

General

ZYXI

Zynex Announces Tricare Temporary Payment Suspension Update; Tricare To Continue Temporary Payment Suspension While Conducting Further Review

Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has outperformed the market over the past 15 years by 6.35% on an annualized basis producing an average annual return of 18.78%. Currently, Home Depot has a market capitalization of $369.96 billion. 
Buying $100 In HD: If an investor had bought $100 of HD stock 15 years ago, it would be worth $1,327.56 today based on a price of $371.85 for HD at the time of writing.
<h3>Home Depot's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751490924_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Home Depot 15 Years Ago Would Be Worth Today

Nuveen Insured California Premium Fund Ii

Northann Regains Compliance With NYSE Guidelines On Audit Opinion Disclosure

Xponential Fitness Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) shares are rising in extended trading Wednesday after the company disclosed that the Securities and Exchange Commission (SEC) concluded an investigation <a href="https://www.benzinga.com/quote/XPOF">without taking action</a>.
What Happened: After market close on Wednesday, fitness franchisor Xponential Fitness said in a filing that the SEC completed its investigation of the company, which began in late 2023, without action.
In December 2023, the SEC requested that Xponential Fitness provide certain documents. The company said it fully cooperated with the regulator&#8217;s investigation over the past 18 months and was informed on Tuesday that no action would be taken.
Xponential Fitness shares were up 22.12% in after-hours, trading at $9.11 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
<h1 class="wp-block-heading">How To Buy XPOF Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, Xponential Fitness is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/news/25/07/46223739/options-exercise-calvin-mcdonald-at-lululemon-athletica-realizes-3-62m">Options Exercise: Calvin McDonald At Lululemon Athletica Realizes $3.62M</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Andrea666">Photology1971</a>/Shutterstock.com

Movers

XPOF

Xponential Fitness Stock Jumps After SEC Investigation Concludes Without Action

Zenvia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) ZENVIA Q1 EPS BRL0.07 per share Up From BRL-1.10 YoY &nbsp;

Earnings

Earnings Beats

ZENV

ZENVIA Q1 EPS BRL0.07 Up From BRL-1.10 YoY

TPG Completes Acquisition of AT&T's 70% Stake in DIRECTV

<h3>Gainers</h3>
<ul>
<li>Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) stock moved upwards by 20.6% to $9.0 during Wednesday's after-market session. The market value of their outstanding shares is at $257.4 million. </li>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) stock increased by 9.17% to $5.95. The company's market cap stands at $126.7 million. </li>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) shares increased by 6.0% to $0.61. The company's market cap stands at $7.9 million. </li>
<li>Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) shares rose 4.99% to $1.68. The market value of their outstanding shares is at $49.1 million. </li>
<li>Alliance Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AENT#NASDAQ">AENT</a>) stock increased by 4.82% to $4.78. The market value of their outstanding shares is at $210.9 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares rose 4.24% to $2.95. The company's market cap stands at $111.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) stock fell 12.1% to $2.49 during Wednesday's after-market session. The market value of their outstanding shares is at $131.8 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares decreased by 6.51% to $1.15. The market value of their outstanding shares is at $17.0 million. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares fell 5.85% to $0.22. The company's market cap stands at $23.2 million. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) stock decreased by 5.36% to $9.01. The company's market cap stands at $256.8 million. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock decreased by 5.06% to $0.3. The company's market cap stands at $80.5 million. </li>
<li>Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) stock decreased by 4.69% to $1.83. The company's market cap stands at $89.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AENT

AGAE

GDHG

MAMO

RYET

TLYS

YSXT

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares increased by 58.9% to $1.97 during Wednesday's after-market session. The market value of their outstanding shares is at $20.4 million. </li>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares rose 14.6% to $0.64. The market value of their outstanding shares is at $7.8 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares increased by 7.72% to $3.2. The company's market cap stands at $414.4 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) shares moved upwards by 7.59% to $2.46. The company's market cap stands at $189.2 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares increased by 7.42% to $5.64. The market value of their outstanding shares is at $21.3 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock moved upwards by 6.77% to $2.6. The company's market cap stands at $97.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares decreased by 23.4% to $1.64 during Wednesday's after-market session. The company's market cap stands at $74.8 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock declined by 15.67% to $3.5. The company's market cap stands at $3.8 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 12.44% to $1.37. The company's market cap stands at $282.9 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock declined by 7.46% to $2.73. The company's market cap stands at $4.8 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares declined by 7.1% to $0.23. The market value of their outstanding shares is at $2.9 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 6.58% to $1.42. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CERS

FGEN

IMAB

MIRA

SERA

SONN

VERO

VTAK

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>The Generation Essentials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGE#NYSE">TGE</a>) shares moved upwards by 30.2% to $9.42 during Wednesday's after-market session. The market value of their outstanding shares is at $411.0 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares increased by 10.52% to $0.21. The company's market cap stands at $32.5 million. </li>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) stock rose 9.18% to $1.07. The company's market cap stands at $78.6 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock increased by 6.29% to $2.87. The company's market cap stands at $5.6 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock moved upwards by 6.25% to $0.34. The market value of their outstanding shares is at $5.5 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock moved upwards by 4.99% to $0.21. The company's market cap stands at $5.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Micropolis Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) shares declined by 7.2% to $2.82 during Wednesday's after-market session. The company's market cap stands at $103.2 million. </li>
<li>Li Bang International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBGJ#NASDAQ">LBGJ</a>) shares fell 6.63% to $1.41. The market value of their outstanding shares is at $27.3 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) shares declined by 6.44% to $2.47. The company's market cap stands at $36.9 million. </li>
<li>WF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WXM#NASDAQ">WXM</a>) stock fell 5.96% to $3.63. The market value of their outstanding shares is at $22.2 million. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares decreased by 5.72% to $6.43. The market value of their outstanding shares is at $20.0 million. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) stock declined by 5.62% to $0.58. The market value of their outstanding shares is at $4.2 million. The company's, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXG

BGLC

HTOO

IPDN

LASE

LBGJ

MCRP

SCWO

YGMZ

ZBAI

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares moved upwards by 41.6% to $3.78 during Wednesday's after-market session. The company's market cap stands at $19.4 million. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) stock moved upwards by 5.1% to $0.21. The company's market cap stands at $8.6 million. </li>
<li>Fatpipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATN#NASDAQ">FATN</a>) shares increased by 4.99% to $9.45. The company's market cap stands at $125.0 million. </li>
<li>CSP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSPI#NASDAQ">CSPI</a>) shares increased by 4.97% to $12.66. The company's market cap stands at $120.6 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock increased by 3.96% to $0.42. The market value of their outstanding shares is at $16.6 million. </li>
<li>Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) shares rose 3.95% to $21.0. The company's market cap stands at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) shares declined by 11.6% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $12.7 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares fell 8.34% to $5.5. The company's market cap stands at $7.6 million. </li>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) stock fell 5.99% to $55.0. The market value of their outstanding shares is at $278.9 million. </li>
<li>Electro-Sensors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELSE#NASDAQ">ELSE</a>) stock fell 4.97% to $4.4. The market value of their outstanding shares is at $14.6 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) stock decreased by 4.38% to $0.86. The market value of their outstanding shares is at $16.9 million. </li>
<li>Youxin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) stock declined by 4.37% to $0.44. The market value of their outstanding shares is at $16.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMNR

BNAI

BNZI

CSPI

ELSE

FATN

LCFY

MINM

Penguin Solutions, Inc. - Ordinary Shares

PENG

SMSI

YAAS

12 Information Technology Stocks Moving In Wednesday's After-Market Session

Zenvia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) Q1 Revenue BRL296M Up From BRL213M YoY &nbsp;

ZENVIA Q1 Revenue BRL296M Up From BRL213M YoY

Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) reported production and delivery numbers for the second quarter after the market close on Wednesday. Here&#8217;s what you <a href="https://www.benzinga.com/pressreleases/25/07/n46232842/lucid-announces-q2-production-deliveries-sets-date-for-second-quarter-2025-results">need to know</a>.
What To Know: Lucid said it produced 3,863 vehicles in the second quarter, up from 2,212 vehicles produced in the <a href="https://www.benzinga.com/news/earnings/25/05/45237817/lucid-q1-earnings-revenue-miss-smaller-than-expected-loss-ev-maker-reaffirms-fy25-production-guidance-of-20000-vehicles">first quarter</a>. The electric vehicle maker reported total second-quarter deliveries of 3,309 vehicles, up from 3,109 in the first quarter. Deliveries came in below analyst estimates of 3,611, according to Reuters.
Lucid also scheduled its second-quarter financial results for after the market close on Aug. 5. Analysts expect the company to report a loss of 21 cents per share and revenue of $297.06 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates.
In the first quarter, Lucid reported mixed results, including revenue of $235.05 million versus estimates of $250 million, and a loss of 20 cents per share versus estimates for a loss of 23 cents per share. 
The company ended the quarter with approximately $5.76 billion in total liquidity and said momentum continued to build during the period. 
Lucid said last quarter that it&#8217;s continuing to target total production of approximately 20,000 vehicles in 2025.
LCID Price Action:&nbsp;<a href="http://benzinga.com/quote/lcid" target="_blank" rel="noreferrer noopener">Lucid shares</a>&nbsp;closed Wednesday up 0.99% at $2.05, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The stock was flat in after-hours despite reportedly missing delivery estimates. Lucid shares remain down approximately 32% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46224223/rivians-production-dips-for-next-gen-models-volkswagen-infusion-boosts-outlook">Rivian&#8217;s Production Dips For Next-Gen Models, Volkswagen Infusion Boosts Outlook</a></li>
</ul>
Photo: courtesy of Lucid.

After-Hours Center

LCID

Lucid Reports Q2 Production, Delivery Numbers, Shares Stall

Electric vehicle giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is seeing weaker demand for its vehicles in the United States for numerous reasons, including increased competition from foreign automakers launching <a href="https://www.benzinga.com/topic/electric-vehicle">new vehicles in the United States.</a>
While Tesla&#8217;s foe, BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), poses a<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46105919/byd-beats-tesla-in-europe-never-been-such-a-product-offensive-done" target="_blank" rel="noopener"> threat to Tesla's global dominance,</a> it could be another Asian automaker that disrupts Tesla in the United States.
What Happened: On Wednesday, Tesla <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46221375/tesla-stock-jumps-on-strong-q2-deliveries">reported second-quarter </a>deliveries of 384,122 units, down 13.5% year-over-year.
While this was the company's global total, recent reports indicate declining sales in the United States, which may be related to CEO Elon Musk&#8216;s increasing involvement in politics and boycotts against the EV brand that occurred during the first half of 2025.
One automotive company seeing an increase in automotive sales, particularly electric vehicles, is Hyundai Motor Company (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>).
The South Korean company reported a record 439,280 vehicles sold in the U.S. in the first half of 2025, up 10% year-over-year.
"We just wrapped up the strongest first half of Hyundai's history," Hyundai North American operations CEO Randy Parker said, as shared by <a href="https://electrek.co/2025/07/01/hyundai-selling-more-vehicles-than-ever-as-us-made-evs-arrive/">Electrek</a>.
Along with achieving its best first half since launching in 1986, Hyundai also reported record sales for the second quarter and the month of June, at 235,726 units and 69,702 units, respectively.
While not all Hyundai vehicles were electric, the increased sales come as a new EV plant in Georgia ramps up production after opening in March.
Hyundai's Ioniq 5 EV had 19,092 sales in the first half of the year, up 2% year-over-year.
The company's Ioniq 9, its first three-row electric SUV, began deliveries in May and had 1,013 units sold in the first six months of the year.
Parker said Hyundai is "building momentum with every mile and an increasing lineup of American-made vehicles and new marketing campaigns are helping to win over consumers.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/45855866/hyundai-secures-one-year-rare-earth-minerals-supply-avoids-supply-chain-disruption-report">Hyundai Secures One-Year Rare Earth Minerals Supply, Avoids Supply Chain Disruption: Report</a>
Why It's Important: Hyundai's new Georgia plant can produce up to 300,000 vehicles annually, with capabilities to expand to 500,000 units annually.
The auto company has been cutting lease prices on the Ioniq 5, making it one of the most affordable EVs on the market, with deals starting at $170 per month. The vehicle has starting prices of $42,500 to $58,100, depending on the specifications.
The starting price for the Ioniq compares to that of the Tesla Model Y and, in many cases, comes in at a lower cost, depending on specifications and incentives.  
In 2024, Tesla had the two top-selling EVs in the United States. The Ioniq 5 was the fourth-best-selling EV in America in 2024 at 44,400 units sold, a figure that was up 30.9% year-over-year.
Of the vehicles in the top 10 that had been sold the previous year, the Ioniq 5 ranked third for year-over-year increase.
Hyundai sold 30,065 more electric vehicles in the U.S. in 2025 than it did the previous year, trailing only the unit growth of Honda (+40,408) and General Motors (+38,543).
Hyundai's U.S. EV market share of 4.7% in 2024 trailed only Tesla (48.7%), Ford (7.5%) and Chevrolet (5.2%).
With the new EV launch and increased production capabilities, Hyundai looks to be a serious competitor to Tesla in the United States and could also start to chip away at the market share of Ford and General Motors.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/management/25/05/45176283/warren-buffett-is-getting-richer-in-2025-and-its-not-because-of-apple-how-one-chinese-holding-is-helping">Warren Buffett Is Getting Richer In 2025 — And It&#8217;s Not Because Of Apple: How One Chinese Holding Is Helping</a></li>
</ul>
Photo: Shutterstock

Long Ideas

BYDDY

HYMTF

TSLA

BYD Isn't Tesla's Only Asian Threat — This EV Maker Is Smashing Records

In the last three months, 5 analysts have published ratings on Cushman &amp; Wakefield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWK#NYSE">CWK</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $12.7, a high estimate of $14.50, and a low estimate of $9.00. Highlighting a 7.97% decrease, the current average has fallen from the previous average price target of $13.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1751490073_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cushman &amp; Wakefield. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Richard Hill</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Richard Hill</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Anthony Paolone</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cushman &amp; Wakefield. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Cushman &amp; Wakefield compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Cushman &amp; Wakefield's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cushman &amp; Wakefield's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CWK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cushman &amp; Wakefield analyst ratings.</a>
<h2>Discovering Cushman &amp; Wakefield: A Closer Look</h2>
Cushman &amp; Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.
<h3>Breaking Down Cushman &amp; Wakefield's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Cushman &amp; Wakefield displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 4.57%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: Cushman &amp; Wakefield's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.08%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cushman &amp; Wakefield's ROE stands out, surpassing industry averages. With an impressive ROE of 0.11%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Cushman &amp; Wakefield's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.03% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cushman &amp; Wakefield's debt-to-equity ratio surpasses industry norms, standing at 1.84. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

5 Analysts Have This To Say About Cushman & Wakefield

Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.56, a high estimate of $58.00, and a low estimate of $40.00. A decline of 8.86% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1751490066_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Zions Bancorp among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Underperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Jennifer Demba</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$53.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$58.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zions Bancorp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Zions Bancorp compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Zions Bancorp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zions Bancorp's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZION/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zions Bancorp analyst ratings.</a>
<h2>Delving into Zions Bancorp's Background</h2>
Zions Bancorporation is a regional US bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions focuses primarily on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
<h3>Financial Milestones: Zions Bancorp's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Zions Bancorp's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 7.14%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Zions Bancorp's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 21.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Zions Bancorp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.71% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Zions Bancorp's debt-to-equity ratio is below the industry average at 0.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZION

9 Analysts Assess Zions Bancorp: What You Need To Know

10 analysts have shared their evaluations of Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ally Financial and provided 12-month price targets. The average target is $41.6, accompanied by a high estimate of $59.00 and a low estimate of $32.00. Highlighting a 3.03% decrease, the current average has fallen from the previous average price target of $42.90. 
<img src="https://www.benzinga.com/files/images/story/2025/1751490058_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Ally Financial among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$32.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Brandon Berman</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Giuliano Bologna</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$41.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ally Financial. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ally Financial compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Ally Financial's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ally Financial's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ally Financial analyst ratings.</a>
<h2>Unveiling the Story Behind Ally Financial</h2>
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
<h3>Unraveling the Financial Story of Ally Financial</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Ally Financial's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -20.15%. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -14.42%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Ally Financial's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.15%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ally Financial's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.13%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ally Financial's debt-to-equity ratio is below the industry average at 1.6, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLY

Expert Outlook: Ally Financial Through The Eyes Of 10 Analysts

In the last three months, 8 analysts have published ratings on Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $161.7, with a high estimate of $191.00 and a low estimate of $136.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.53%. 
<img src="https://www.benzinga.com/files/images/story/2025/1751490043_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Hess among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitin Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$184.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$173.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$191.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$136.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$146.58</td>
<td>$164.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hess. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hess compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Hess's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Hess's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hess analyst ratings.</a>
<h2>About Hess</h2>
Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2024, the company reported net proved reserves of 1.44 billion barrels of oil equivalent. Net production averaged 481 thousand barrels of oil equivalent per day in 2024, at a ratio of 79% oil and natural gas liquids and 21% natural gas.
<h3>Hess's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3M period, Hess faced challenges, resulting in a decline of approximately -12.0% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Hess's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hess's ROE stands out, surpassing industry averages. With an impressive ROE of 3.78%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Hess's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.6% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.82, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hess Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

4 analysts have expressed a variety of opinions on WisdomTree (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WT#NYSE">WT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for WisdomTree, revealing an average target of $10.22, a high estimate of $11.90, and a low estimate of $8.50. This current average has increased by 8.96% from the previous average price target of $9.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1751490030_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of WisdomTree by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$9.75</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.90</td>
<td>$9.50</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$9.50</td>
<td>$8.50</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.50</td>
<td>$9.75</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to WisdomTree. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of WisdomTree compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of WisdomTree's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WisdomTree analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About WisdomTree</h2>
WisdomTree Inc is a financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. It offers a broad range of ETFs and exchange-traded products (ETPs). The firm also engages in developing next-generation digital products and structures, including digital funds and tokenized assets, as well as its blockchain-native digital wallet, WisdomTree Prime. The Company conducts business under a single operating segment as an ETP sponsor and asset manager.
<h3>WisdomTree: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, WisdomTree showcased positive performance, achieving a revenue growth rate of 11.61% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 22.77%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): WisdomTree's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 6.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.39%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.23.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying WisdomTree: Insights From 4 Analyst Reviews

Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) has outperformed the market over the past 20 years by 1.93% on an annualized basis producing an average annual return of 10.4%. Currently, Starbucks has a market capitalization of $107.06 billion. 
Buying $1000 In SBUX: If an investor had bought $1000 of SBUX stock 20 years ago, it would be worth $7,275.40 today based on a price of $94.21 for SBUX at the time of writing.
<h3>Starbucks's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751490025_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SBUX

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

In the current session, the stock is trading at $56.14, after a 0.75% increase. Over the past month, EQT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) stock increased by 1.17%, and in the past year, by 54.57%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1751490019_0.png" alt="Past Year Chart" />

<h3>EQT P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
EQT has a better P/E ratio of 91.34 than the aggregate P/E ratio of 16.12 of the Oil, Gas &amp; Consumable Fuels industry. Ideally, one might believe that EQT Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751490019_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into EQT Inc's Price Over Earnings

Press Releases

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Leap Therapeutics Reports First Quarter 2025 Financial Results

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Comments

Leap Therapeutics

Notizie

Ultime notizie per Leap Therapeutics (NASDAQ:LPTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO